The abstract is read at the publisher; the summary is JClub's.
Genetic studies in people with type 2 diabetes show MASLD heterogeneity, with multiple genome-wide association loci linked to liver fat, severity, and progression through distinct biological pathways.
- Why it matters: Conventional metabolic risk factors do not fully explain why MASLD varies in clinical course among diabetes patients, limiting mechanism-based risk assessment and management.
- What they did: The review synthesizes evidence from family studies, genome-wide association studies, imaging genetics, and Mendelian randomisation, emphasizing cautious causal interpretation and gene-diabetes or gene-environment interactions.
- The result: MASLD genetics supports a mechanism-based framework suggesting that similar hepatic steatosis can reflect different processes, informing risk stratification, therapeutic target discovery, and genotype-informed care.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.